These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 17617276)

  • 1. Pre-exposure prophylaxis for HIV infection: what if it works?
    Paxton LA; Hope T; Jaffe HW
    Lancet; 2007 Jul; 370(9581):89-93. PubMed ID: 17617276
    [No Abstract]   [Full Text] [Related]  

  • 2. Tolerability of two different combinations of antiretroviral drugs including tenofovir used in occupational and nonoccupational postexposure prophylaxis for HIV.
    Burty C; Prazuck T; Truchetet F; Christian B; Penalba C; Salmon-Ceron D; Yazdanpanah Y; May T; Rabaud C
    AIDS Patient Care STDS; 2010 Jan; 24(1):1-3. PubMed ID: 20095911
    [No Abstract]   [Full Text] [Related]  

  • 3. New once-daily HIV combination better tolerated.
    Expert Rev Anti Infect Ther; 2004 Dec; 2(6):826. PubMed ID: 15566325
    [No Abstract]   [Full Text] [Related]  

  • 4. HIV transmission may be prevented by intravaginal tenofovir ring.
    Parks L
    Future Med Chem; 2012 Dec; 4(18):2239. PubMed ID: 23359902
    [No Abstract]   [Full Text] [Related]  

  • 5. Tenofovir in HIV-infected children. Antiretroviral efficacy, but beware of adverse effects on bone and the kidneys.
    Prescrire Int; 2014 May; 23(149):124-5. PubMed ID: 24926511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
    Bayonne Kombo ES; Gathse A
    Med Mal Infect; 2013 Mar; 43(3):134-5. PubMed ID: 23434355
    [No Abstract]   [Full Text] [Related]  

  • 7. [Preexposure prophylaxis for HIV infection--current data and recommendations].
    Kümmerle T; Fätkenheuer G
    Dtsch Med Wochenschr; 2012 Nov; 137(44):2285-8. PubMed ID: 23093400
    [No Abstract]   [Full Text] [Related]  

  • 8. Raltegravir as effective as efavirenz in 144-week data.
    AIDS Patient Care STDS; 2009 Aug; 23(8):679-80. PubMed ID: 19694035
    [No Abstract]   [Full Text] [Related]  

  • 9. [3 years' data of tenofovir. Confirmed as a valuable building block].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():30-1. PubMed ID: 15373042
    [No Abstract]   [Full Text] [Related]  

  • 10. Determination of kidney function before tenofovir initiation: four-fold difference in need of tenofovir dose reduction depending on method used.
    van Griensven J; Sopheak T; Koole O; Verpooten GA; Lynen L
    J Acquir Immune Defic Syndr; 2011 Jun; 57(2):e21-3. PubMed ID: 21709448
    [No Abstract]   [Full Text] [Related]  

  • 11. Tenofovir: a pill to prevent HIV?
    Bonn D
    Lancet Infect Dis; 2005 Feb; 5(2):78. PubMed ID: 15702509
    [No Abstract]   [Full Text] [Related]  

  • 12. Elvucitabine data released at CROI.
    AIDS Patient Care STDS; 2010 Mar; 24(3):198. PubMed ID: 20235383
    [No Abstract]   [Full Text] [Related]  

  • 13. Pre-exposure prophylaxis works--it's time to deliver.
    Beyrer C; Bekker LG; Pozniak A; Barré-Sinoussi F
    Lancet; 2015 Apr; 385(9977):1482-4. PubMed ID: 25933264
    [No Abstract]   [Full Text] [Related]  

  • 14. Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify ongoing therapy just to use one less tablet. Better adherence than with separate dosing has not been demonstrated, while reduced efficacy is plausible.
    Prescrire Int; 2009 Jun; 18(101):105. PubMed ID: 19637416
    [No Abstract]   [Full Text] [Related]  

  • 15. AIDS. Promote HIV chemoprophylaxis research, don't prevent it.
    Grant RM; Buchbinder S; Cates W; Clarke E; Coates T; Cohen MS; Delaney M; Flores G; Goicochea P; Gonsalves G; Harrington M; Lama JR; MacQueen KM; Moore JP; Peterson L; Sanchez J; Thompson M; Wainberg MA
    Science; 2005 Sep; 309(5744):2170-1. PubMed ID: 16195446
    [No Abstract]   [Full Text] [Related]  

  • 16. Preexposure prophylaxis reduces HIV risk in injection-drug users.
    Rosenberg K
    Am J Nurs; 2013 Sep; 113(9):17. PubMed ID: 23985594
    [No Abstract]   [Full Text] [Related]  

  • 17. A second chance for microbicides.
    Baleta A
    Lancet; 2007 Jul; 370(9581):17-8. PubMed ID: 17632853
    [No Abstract]   [Full Text] [Related]  

  • 18. Second tenofovir phase III study for the chronic HBV reaches primary endpoint.
    AIDS Patient Care STDS; 2007 Aug; 21(8):607-8. PubMed ID: 17907310
    [No Abstract]   [Full Text] [Related]  

  • 19. Tenofovir-associated proteinuria.
    Kelly MD; Gibson A; Bartlett H; Rowling D; Patten J
    AIDS; 2013 Jan; 27(3):479-81. PubMed ID: 22874515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microbicides are promoted as offering a 'female-controlled' HIV prevention method: so can they revolutionize the HIV crisis of young women in Kenya?
    Raphael MC
    J Public Health (Oxf); 2012 Dec; 34(4):625-30. PubMed ID: 23055541
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.